Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04430660 · ClinicalTrials.gov registry record · NA
Evaluating Glial Acetate Metabolism as a Biomarker of Hypoglycemic Complications in Diabetic Patients
A NA study, sponsored by Pennington Biomedical Research Center.
- Completed
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT04430660: Completed NA study, sponsored by Pennington Biomedical Research Center.
NCT04430660 is a NA study that has completed, run by Pennington Biomedical Research Center. The registered enrollment target is 8 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04430660, a NA study, has completed, sponsored by Pennington Biomedical Research Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
A recent pilot study, GLIMPSE (NCT02690168), was recently completed which demonstrated that the rate of glial acetate metabolism (GAM) is closely associated with susceptibility to fasting-induced hypoglycemia in healthy adults. Insulin-induced hypoglycemia is a common complication of diabetes treatment and is a major barrier to the maintenance of healthy glucose levels in individuals with diabetes. The primary purpose of the study is to test the proof-of-concept that there is an association between the rate of GAM and susceptibility to insulin-induced hypoglycemia. In order to observe such a relationship the rate of GAM will be measured in a patient population known to frequently experience hypoglycemia, i.e., individuals with type 1 diabetes mellitus (T1DM).
Interventions
- OTHER 13C-MRS procedure/Acetate infusion
- DEVICE Continuous glucose monitoring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-08-19 |
| Est. Completion | 2022-05-04 |
| Phase | NA |
What the finished NCT04430660 record still lists
NCT04430660 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which 13C-MRS procedure/Acetate infusion is the first listed.
NCT04430660 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04430660 about?
NCT04430660 is a clinical study titled "Evaluating Glial Acetate Metabolism as a Biomarker of Hypoglycemic Complications in Diabetic Patients". A recent pilot study, GLIMPSE (NCT02690168), was recently completed which demonstrated that the rate of glial acetate metabolism (GAM) is closely associated with susceptibility to fasting-induced hypoglycemia in healthy adults. Insulin-induced hypoglycemia is a common complication of diabetes treatm...
What is the current status of trial NCT04430660?
This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2020-08-19. Estimated completion is 2022-05-04.
What interventions are being tested in trial NCT04430660?
The interventions under investigation include: 13C-MRS procedure/Acetate infusion (OTHER), Continuous glucose monitoring (DEVICE).
Who is sponsoring clinical trial NCT04430660?
This trial is sponsored by Pennington Biomedical Research Center, which has 258 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04430660's enrollment target sits among peer trials
8 1976th of 2000 higher than 19 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI